Search results
Results from the WOW.Com Content Network
Meclizine is effective in inhibiting nausea, vomiting, and dizziness caused by motion sickness. [10] The drug is safe for treating nausea in pregnancy and is a first-line therapy for this use. [11] [12] Meclizine may not be strong enough for especially sickening motion stimuli, and second-line defenses should be tried in those cases. [13]
Cinnarizine's antagonistic effects of D2 dopamine receptors in the striatum leads to symptoms of depression, tremor, muscle rigidity, tardive dyskinesia, and akathisia. 17 of 100 new parkinsonism cases are linked to administration of either cinnarizine or flunarizine. [5] Drug induced parkinsonism is the second leading cause of parkinsonism. [22]
Tizanidine, sold under the brand name Zanaflex among others, is an alpha-2 (α 2) adrenergic receptor agonist, [2] similar to clonidine, that is used to treat muscle spasticity due to spinal cord injury, multiple sclerosis, and spastic cerebral palsy. [3]
Anticholinergic drugs are used to treat a variety of conditions: Dizziness (including vertigo and motion sickness-related symptoms) Extrapyramidal symptoms, a potential side-effect of antipsychotic medications; Gastrointestinal disorders (e.g., peptic ulcers, diarrhea, pyloro spasm, diverticulitis, ulcerative colitis, nausea, and vomiting)
Medicare recipients who take expensive prescriptions will get a break this year with a $2,000 cap on drug costs.. The cap will reduce out-of-pocket spending for potentially millions of older ...
Many people experience lightheadedness or dizziness at some point in their lifetime, but if you are living with a neurodegenerative condition, like Parkinson’s disease, those symptoms could mean ...
There has been a study that suggests antipsychotics are associated with possible cortical reconfiguration and gray matter loss, [19] but correlational data also suggests patients who consume antipsychotics, like people with schizophrenia, tend to engage in unhealthy habits like smoking which may exacerbate gray matter loss.
In clinical trials, GLP-1 drug tirzepatide reduced sleep apnea events by as much as two-thirds over the course of 52 weeks in patients with obstructive sleep apnea. Patients taking a placebo ...